Bij de cursus FA-BA304 werd gebruik gemaakt van het leerboek: Molecular Biology of Cancer door Lauren Pecorino 4e editie.
In deze samenvatting zijn alle hoofdstukken en paragrafen die als bronnen diende voor de colleges uit collegejaar 2019/2020 samengevat.
In de samenvatting is per hoofdstuk...
,Inhoud
H2: DNA structure and stability: mutations versus repair ...................................................................... 5
2.1 Gene structure- two parts of a gene: the regulatory region and the coding region..................... 5
2.2 Mutations ...................................................................................................................................... 5
2.3 Carcinogenic agents ...................................................................................................................... 6
2.4 DNA repair and predisposition to cancer ...................................................................................... 7
One-step repair ............................................................................................................................... 7
Nucleotide excision repair (NER) ..................................................................................................... 7
Base excision repair (BER) ............................................................................................................... 8
Mismatch repair (MMR) .................................................................................................................. 8
Recombinational repair ................................................................................................................... 8
2.5 Conventional therapies: chemotherapy and radiation therapy.................................................... 8
2.6 Strategies that target DNA repair pathways ................................................................................. 8
Synthetic lethal strategies ............................................................................................................... 8
Combination therapies .................................................................................................................... 8
H3: Regulation of gene expression.......................................................................................................... 9
3.1 Transcription factors and transcriptional regulation .................................................................... 9
3.2 Chromatin structure .................................................................................................................... 10
3.3 epigenetic regulation of transcription......................................................................................... 10
3.4 Evidence of a role for epigenetics in carcinogenesis ................................................................... 11
3.5 Long non coding RNAs ................................................................................................................. 11
3.6 MicroRNAs (miRNAs) and regulation of mRNA expression ......................................................... 12
3.7 Telomeres and telomerase .......................................................................................................... 12
3.8 Epigenomic and histonomic drugs. ............................................................................................. 13
3.9 Non-coding RNAs for diagnosis. .................................................................................................. 13
3.10 Telomerase inhibitors................................................................................................................ 13
H4: Growth factor signaling and oncogenes ......................................................................................... 14
4.1: Epidermal growth factor signaling: an important paradigm ...................................................... 14
4.2 Oncogenes ................................................................................................................................... 17
4.3 Kinases as drug targets ................................................................................................................ 18
H5: The cell cycle ................................................................................................................................... 20
5.1 Cyclins and cyclin-dependent kinases (cdks)............................................................................... 20
5.2 Mechanisms of cdk regulation .................................................................................................... 20
5.3 Progression through the G1 checkpoint...................................................................................... 21
5.4 The G2 checkpoint........................................................................................................................ 22
Michelle
2
, 5.5 The mitotic checkpoint ................................................................................................................ 23
5.6 The cell cycle and cancer ............................................................................................................. 24
5.7 Cyclin-dependent kinase inhibitors ............................................................................................. 24
5.8 Other cell cycle kinase targets ..................................................................................................... 24
5.9 Inhibitors of the mitotic spindle .................................................................................................. 24
H6: Growth inhibition and tumor suppressor genes............................................................................. 25
6.1 Definitions of tumor suppressor genes ....................................................................................... 25
6.2 The retinoblastoma gene ............................................................................................................ 25
6.3 Mutations in the RB pathway and cancer ................................................................................... 25
6.4 The p53 pathway ......................................................................................................................... 25
6.5 Mutations in the p53 pathway and cancer ................................................................................. 29
6.6 Interaction of DNA viral protein products with RB and p53 ....................................................... 30
6.7 targeting of the p53 pathway ...................................................................................................... 30
H7: Apoptosis ........................................................................................................................................ 32
7.1 Molecular mechanisms of apoptosis ........................................................................................... 32
7.2 Apoptosis and cancer .................................................................................................................. 36
7.3 Apoptosis and chemotherapy ..................................................................................................... 37
7.4 apoptotic drugs ........................................................................................................................... 37
H9: Metastasis ....................................................................................................................................... 39
9.1 How do tumors spread? .............................................................................................................. 39
9.2 The process of metastase ............................................................................................................ 39
9.3 Invasion and the epithelial-mesenchymal transition .................................................................. 40
Induction of EMT ........................................................................................................................... 40
Tools of invasion: cell adhesion molecules, integrins and proteases ........................................... 40
9.4 Intravasation................................................................................................................................ 41
9.5 Transport ..................................................................................................................................... 41
9.6 Extravasation ............................................................................................................................... 41
9.7 Metastatic colonization ............................................................................................................... 42
The pre-metastatic niche .............................................................................................................. 42
Exosomes ....................................................................................................................................... 42
Metastasis suppressor genes ........................................................................................................ 42
Therapeutic strategies ................................................................................................................... 42
9.8 Metalloproteinase inhibitors (MPIs) ........................................................................................... 42
c-MET inhibitors for blocking EMT ................................................................................................ 42
9.9 Strategies for restoring metastasis suppressors ......................................................................... 43
Michelle
3
, 9.10 Targeting several steps of metastasis at once .......................................................................... 43
H10 Angiogenesis .................................................................................................................................. 44
10.1 The angiogenic switch ............................................................................................................... 44
Angiogenic inducers ...................................................................................................................... 44
Angiogenic inhibitors ..................................................................................................................... 45
10.2 Cell behavior during angiogenic sprouting ................................................................................ 46
10.3 Other means of tumor neovascularization ............................................................................... 46
10.4 Anti-angiogenic therapy ............................................................................................................ 47
10.5 Vascular targeting by vascular disrupting agents ...................................................................... 47
H12: Tumor immunology and immunotherapy .................................................................................... 48
12.1 Lymphocytes: B cells and T cells ................................................................................................ 48
12.2 The tumor suppressive roles of the immune system ................................................................ 48
12.3 Immune checkpoints ................................................................................................................. 49
12.4 Cancer immunoediting and tumor promotion .......................................................................... 49
12.5 Mechanisms of avoiding immune destruction .......................................................................... 50
12.6 Therapeutic antibodies.............................................................................................................. 50
12.7 Cancer vaccines ......................................................................................................................... 50
12.8 Immune checkpoint blockades.................................................................................................. 51
12.9 Adoptive T-cell transfer, modified T-cell receptors, and chimeric antigen receptors .............. 52
12.10 Oncolytic viruses and virotherapy ........................................................................................... 52
Michelle
4
Voordelen van het kopen van samenvattingen bij Stuvia op een rij:
Verzekerd van kwaliteit door reviews
Stuvia-klanten hebben meer dan 700.000 samenvattingen beoordeeld. Zo weet je zeker dat je de beste documenten koopt!
Snel en makkelijk kopen
Je betaalt supersnel en eenmalig met iDeal, creditcard of Stuvia-tegoed voor de samenvatting. Zonder lidmaatschap.
Focus op de essentie
Samenvattingen worden geschreven voor en door anderen. Daarom zijn de samenvattingen altijd betrouwbaar en actueel. Zo kom je snel tot de kern!
Veelgestelde vragen
Wat krijg ik als ik dit document koop?
Je krijgt een PDF, die direct beschikbaar is na je aankoop. Het gekochte document is altijd, overal en oneindig toegankelijk via je profiel.
Tevredenheidsgarantie: hoe werkt dat?
Onze tevredenheidsgarantie zorgt ervoor dat je altijd een studiedocument vindt dat goed bij je past. Je vult een formulier in en onze klantenservice regelt de rest.
Van wie koop ik deze samenvatting?
Stuvia is een marktplaats, je koop dit document dus niet van ons, maar van verkoper Michelle1802. Stuvia faciliteert de betaling aan de verkoper.
Zit ik meteen vast aan een abonnement?
Nee, je koopt alleen deze samenvatting voor €6,49. Je zit daarna nergens aan vast.
